Astellas Gene Therapies
Clinical trials sponsored by Astellas Gene Therapies, explained in plain language.
A subsidiary of Astellas Pharma focused on gene therapy development.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Pompe disease study aims to clear path for gene therapy Results expected Jun 2027 (estimated)
-
Experimental gene therapy aims to help boys with rare muscle disease breathe easier
Disease control Recruiting nowThis early-phase trial tests a new gene therapy called ASP2957 for X-linked myotubular myopathy (XLMTM), a rare muscle disease present at birth that often requires a ventilator to breathe. The therapy delivers a healthy copy of the MTM1 gene using a modified virus. Nine boys up t…
Phase 1/2 • Sponsor: Astellas Gene Therapies • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New study aims to uncover hidden liver risks in rare muscle disease
Knowledge-focused Recruiting nowThis study follows about 50 boys under 18 with X-linked myotubular myopathy (XLMTM), a rare genetic muscle condition, to see how often they develop liver problems like cholestasis. No drugs are given—researchers simply collect health data, including liver scans, over one year. Th…
Sponsor: Astellas Gene Therapies • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC